INTRODUCTION {#s1}
============

Breast cancer is the most frequently diagnosed cancer and is the second leading cause of cancer death among females.\[[@R1], [@R2]\] Despite advances in detection and treatment, 20-30% of patients with early-stage breast cancer will become metastatic.\[[@R3]\] The development of targeted therapy for HR-positive and HER2-overexpressing MBC has significantly improved outcomes in these subsets.\[[@R4]-[@R9]\] However, upon development of resistance to these therapies and in the setting of TNBC, cytotoxic chemotherapy remains the backbone of treatment, and long-term outcomes remain poor.\[[@R10]\]

Understanding the genomic drivers of cancer growth is essential to developing new therapies. Further, as tumors become resistant to administered therapies, tumor heterogeneity develops, making genomically-informed therapy even more relevant to the constantly changing landscape of advanced disease. The emerging capability of sequencing multiple cancer-related genes in a tissue-sparing and cost-effective manner and the development of novel targeted therapeutics has made genomically-informed therapy a reality. However, although molecular testing is now routinely performed in many patients with advanced cancer, the use of this knowledge to guide therapy is widely accepted for only a few alterations in specific tumor types. Thus, we need more comprehensive knowledge of genomic changes and their clinical implications.

Through sequencing, we have learned that *TP53* and *PIK3CA* are the most frequently mutated genes in breast cancer.\[[@R11]\] However, the clinical implications of these mutations are not well defined. Because *TP53* is a multifunctional protein, some studies report improved outcomes with mutations while others report the opposite.\[[@R12]\] Similarly, studies report varying outcomes with mutations in *PIK3CA*.\[[@R13]-[@R15]\] The implications of various mutations become even more complex when specific subsets of breast cancer are evaluated. Large patient series with available genomic and clinical outcome data are needed to better understand implications of aberrations in specific genes. Thus, we activated an enterprise-level genomic screening effort. In this study, we reviewed the results of hotspot molecular testing by next-generation sequencing (NGS) of commonly mutated genes in the tumors of 500 patients with MBC. We then correlated the most frequently encountered hotspot mutations with clinical and pathologic characteristics and clinical outcomes to better understand their clinical implications. In this cohort of MBC patients, *TP53*, the most frequently encountered hotspot mutation, was associated with worse clinical outcomes, while *PIK3CA*, the second most frequently encountered hotspot mutation, did not remain a significant predictor of outcomes after multivariable analysis.

RESULTS {#s2}
=======

A total of 605 samples from 500 MBC patients were collected. The primary tumor was tested in most patients (290). Two samples were tested in 103 patients. Of these, the majority of patients (89) had the primary and a metastatic site analyzed. One patient had 3 samples tested (primary, synchronous axillary lymph node, metachronous metastatic disease). Patients who had more than one sample tested were considered mutants for a specific gene if mutations were encountered in any of the samples tested. Sequenom was used exclusively in 109 patients and a 46 or 50 gene Ampliseq Ion Torrent Assay was used exclusively in 374 patients. The genes assessed by each assay are listed is [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

Seventeen patients underwent analysis by both Sequenom and the 46 gene assay. The nine common genes between these two testing methods and their mutation status in each patient are shown in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}. There was mutational disconcordance between the two testing platforms in three of the seventeen cases; however in all of these patients, different sites were analyzed by Sequenom and the Ampliseq 46 panel. In addition, the time interval between obtaining samples from the primary and metastatic tumors in these three patients may be relevant as it is possible that mutations can accumulate within a tumor over time. In one case, the metastatic specimen was collected two years after the primary sample.

[Supplementary Figure 2](#SD1){ref-type="supplementary-material"} illustrates the mutation status of genes between primary tumors and corresponding metastases in the 89 patients that had both sites analyzed. Matched primary and metastatic tumors demonstrated an overall concordance rate of 74% (66/89). The aberrant genes associated with primary-metastasis discordance were identified predominantly in metastatic tumors, with *PIK3CA* and *TP53* being the most frequent discordant genes. There were four cases with gains and one with a loss of *TP53* mutation in metastatic/recurrent tumors compared to the primary. There were five cases with gains and six with losses in *PIK3CA* mutation. There were also four cases with gains and one with a loss in *MAPK* pathway mutation.

Genomic alterations {#s2_1}
-------------------

Genomic alterations that were predicted to be germline variants based on an informatics algorithm that assessed allelic frequency of mutations in tumor samples were excluded ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). The most frequently mutated genes were *TP53* (29.9%), *PIK3CA* (27.2%) and *AKT1* (4.0%). Alterations were also detected in other genes including *ERBB2* (1.3%), *KRAS* (1%), *PTEN* (1%), *HRAS* (0.8%), *SMAD4* (0.8%), *ATM* (0.8%), *NRAS* (0.6%), *FGFR2* (0.5%), *BRAF* (0.4%), *IDH1* (0.4%), *APC* (0.5%), *CDH1* (0.3%), *EGFR* (0.3%), *ERBB4* (0.3%), *FGFR1* (0.3%), *FGFR3* (0.3%), *JAK3* (0.3%), *MLH1* (0.3%), *PTPN11* (0.3%), *SMARCB1* (0.3%), *STK11* (0.3%), and *MET* (0.4 %). Alterations seen by the 46 or 50 gene panels in replace each of the subtypes with each subset of breast cancer are presented in Figure [1](#F1){ref-type="fig"}.

![Spectrum of Mutations Detected by the 46 or 50 Gene Ampliseq Ion Torrent Assay\
Spectrum of mutations and co-mutations detected by the 46 or 50 gene Ampliseq Ion Torrent Assay in the three breast cancer subtypes. **A.** Spectrum of mutations in patients with HR-positive and HER2-negative disease (*N* = 154). **B.** Spectrum of mutations in patients with HER2-positive disease (*N* = 29). **C.** Spectrum of mutations in patients with TNBC (*N* = 47).](oncotarget-07-76362-g001){#F1}

Correlation of frequent mutations with clinical and pathologic characteristics {#s2_2}
------------------------------------------------------------------------------

For clinical analysis, four of the 500 patients were excluded because they did not start systemic therapy at the time of diagnosis. Nine additional patients were excluded because they developed contralateral breast cancer prior to metastatic disease. After exclusion, 343 patients (70.4%) had HR-positive and HER2-negative breast cancer, 55 (11.3%) had HER2-positive disease regardless of HR status and 89 (18.3%) had TNBC. Table [1](#T1){ref-type="table"} summarizes the patient characteristics, overall and by mutation in *TP53*, *PIK3CA* or *AKT1*. Patients with TNBC had a higher rate of *TP53* mutation (58.3%) than HER2-positive (42.4%) and HR-positive (21.7%) patients. Conversely, *PIK3CA* mutation rate was lower in TNBC (9.0%) than HER2-positive (30.9%) and HR-positive (31.2%) disease. All 19 *AKT1* mutated cases were HER2-negative, and 18 out of 19 cases were HR-positive. In patients with grade III tumors, the incidence of *TP53* mutation (39.5%) was higher than the incidence of *PIK3CA* mutation (18.9%) or *AKT1* mutation (2.2%). Similarly, patients with intracranial disease as their first site of distant disease had a higher incidence of *TP53* mutation (57.1%) compared to *PIK3CA* mutation (14.3%) or *AKT1* mutation (0%). There were no significant differences in the mutation rates based on metastatic site tested.

###### Summary of Patient and Clinical Characteristics by Most Frequent Mutations

                                 Overall      TP53 Wild Type   *TP53* Mutated   P Value   *PIK3CA* Wild Type   *PIK3CA* Mutated   P Value   *AKT1* Wild Type   *AKT1* Mutated   P Value
  ------------------------------ ------------ ---------------- ---------------- --------- -------------------- ------------------ --------- ------------------ ---------------- ---------
  **Median Age (Range)**         47 (23-74)   46 (23-74)       48 (26-74)       0.38      47 (23-74)           48 (26-74)         0.14      47 (23-74)         40 (31-63)       0.09
  **Race**                                                                      0.99                                              0.12                                          0.68
   White                         366          204 (70.3)       90 (30.6)                  257 (70.2)           109 (29.8)                   351 (95.9)         15 (4.1)         
   Black                         45           23 (71.9)        9 (28.1)                   35 (87.8)            10 (22.2)                    44 (97.8)          1 (2.2)          
   Hispanic                      56           25 (69.4)        11 (30.6)                  46 (82.1)            10 (17.9)                    53 (94.6)          3 (5.4)          
   Other                         20           13 (68.4)        6 (31.6)                   17 (85.0)            3 (15.0)                     20 (100.0)         0 (0.0)          
  **Gender**                                                                    0.81                                              0.30                                          0.69
   Female                        483          262 (69.5)       115 (30.5)                 353 (73.1)           130 (26.9)                   464 (96.1)         19 (3.9)         
   Male                          4            3 (75.0)         1 (25.0)                   2 (50.0)             2 (50.0)                     4 (100.0)          0 (0.0)          
  **Subtype**                                                                   \<0.01                                            \<0.01                                        0.06
   HR-positive, HER2-negative    343          216 (78.3)       60 (21.7)                  236 (68.8)           107 (31.2)                   325 (94.8)         18 (5.2)         
   HER2-positive                 55           19 (57.6)        14 (42.4)                  38 (69.1)            17 (30.9)                    55 (100.0)         0 (0.0)          
   TNBC                          89           30 (41.7)        42 (58.3)                  81 (91.0)            8 (9.0)                      88 (98.9)          1 (1.1)          
  **Stage at Diagnosis**                                                        0.32                                              0.79                                          0.42
   0                             4            2 (66.7)         1 (33.3)                   3 (75.0)             1 (25.0)                     4 (100.0)          0 (0.0)          
   I                             62           37 (69.8)        16 (30.2)                  44 (71.0)            18 (29.0)                    59 (95.2)          3 (4.8)          
   II                            181          97 (66.4)        49 (33.5)                  127 (70.2)           54 (29.8)                    173 (95.6)         8 (4.4)          
   III                           128          70 (66.7)        35 (33.3)                  98 (76.6)            30 (23.4)                    121 (94.5)         7 (5.5)          
   IV                            111          59 (79.7)        15 (20.3)                  82 (73.9)            29 (26.1)                    110 (99.1)         1 (0.9)          
  **Tumor Histology**                                                           0.12                                              0.61                                          0.52
   Ductal                        401          216 (67.3)       105 (32.7)                 298 (74.3)           103 (25.7)                   386 (96.3)         15 (3.7)         
   Lobular                       44           26 (86.7)        4 (13.3)                   28 (63.6)            16 (36.4)                    42 (95.5)          2 (4.5)          
   Mixed Ductal/Lobular          15           10 (76.9)        3 (23.1)                   10 (66.7)            5 (33.3)                     14 (93.3)          1 (6.7)          
   Metaplastic/Sarcomatoid       7            2 (50.0)         2 (50.0)                   5 (71.4)             2 (28.6)                     6 (85.7)           1 (14.3)         
   Other                         20           11 (84.6)        2 (15.4)                   14 (70.0)            6 (30.0)                     20 (100.0)         0 (0.0)          
  **Tumor Grade**                                                               \<0.01                                            \<0.01                                        0.04
   I                             22           16 (94.1)        1 (5.9)                    10 (45.5)            12 (54.5)                    22 (100.0)         0 (0.0)          
   II                            168          110 (80.3)       27 (19.7)                  106 (63.1)           62 (36.9)                    157 (93.5)         11 (6.5)         
   III                           275          127 (60.5)       83 (39.5)                  223 (81.1)           52 (18.9)                    269 (97.8)         6 (2.2)          
  **Neoadjuvant Chemotherapy**                                                  \<0.01                                            0.11                                          0.04
   Yes                           156          80 (60.6)        52 (39.4)                  121 (77.6)           35 (22.4)                    154 (98.7)         2 (1.3)          
   No                            331          185 (74.3)       64 (25.7)                  234 (70.7)           97 (29.3)                    314 (94.9)         17 (5.1)         
  **Adjuvant Chemotherapy**                                                     0.05                                              0.43                                          0.02
   Yes                           341          189 (66.8)       94 (33.2)                  245 (71.8)           96 (28.2)                    323 (94.7)         18 (5.3)         
   No                            146          76 (77.6)        22 (22.4)                  110 (75.3)           36 (24.7)                    145 (99.3)         1 (0.7)          
  **Type of Surgery**                                                           0.07                                              0.83                                          0.92
   Breast-conserving             126          61 (59.2)        42 (40.8)                  91 (72.2)            35 (27.8)                    120 95.2)          6 (4.8)          
   Mastectomy                    299          166 (71.6)       66 (28.4)                  216 (72.2)           83 (27.8)                    287 (96.0)         12 (4.0)         
  **First Site of Metastasis**                                                  0.01                                              0.19                                          0.15
   Visceral                      181          91 (64.1)        51 (35.9)                  130 (71.8)           51 (28.2)                    175 (96.7)         6 (3.3)          
   Bone                          183          102 (73.9)       36 (26.1)                  126 (68.9)           57 (31.1)                    176 (96.2)         7 (3.8)          
   Soft Tissue                   49           29 (67.4)        14 (32.6)                  41 (83.7)            8 (16.3)                     44 (89.8)          5 (10.2)         
   Brain                         14           6 (42.9)         8 (57.1)                   12 (85.7)            2 (14.3)                     14 (100.0)         0 (0.0)          
   Multiple                      60           37 (84.1)        7 (15.9)                   46 (77.7)            14 (23.3)                    59 (98.3)          1 (1.7)          

Correlation of frequent mutations with patient outcomes {#s2_3}
-------------------------------------------------------

*TP53* mutation was associated with significantly worse LRFS (median 43 *vs* 90 months; *P* \< 0.001), DRFS (median 26 *vs* 43 months; *P* \< 0.001), RFS (median 22 *vs* 42 months; *P* \< 0.001) and OS (median 26 *vs* 51 months; *P* \< 0.001) (Figure [2](#F2){ref-type="fig"}). Conversely, *PIK3CA* mutation was associated with significantly better LRFS (median 90 *vs* 60 months; *P* = 0.019) and a trend towards better DRFS (median 43 *vs* 32 months; *P* = 0.109), RFS (median 41 *vs* 30 months; *P* = 0.074) and OS (median 52 *vs* 40 months; *P* = 0.066) (Figure [3](#F3){ref-type="fig"}). When mutation in *PIK3CA* exon 9 was compared to mutation in *PIK3CA* exon 20, no significant difference was seen in RFS (41 *vs* 43 months; *P* = 0.354) or OS (53 *vs* 64 months; *P* = 0.635). *AKT1* mutation was associated with significantly better DRFS (median 66 *vs* 34 months; *P* = 0.043) and RFS (median 53 *vs* 31 months; *P* = 0.039), but not OS (median 62 *vs* 42 months; *P* = 0.211).

![*TP53* Mutation is Associated with Worse Outcomes\
Kaplan-Meier curves of LRFS, DRFS, RFS and OS in patients with and without *TP53* mutations. *TP53* mutation was associated with significantly worse LRFS, DRFS, RFS and OS.](oncotarget-07-76362-g002){#F2}

In HR-positive patients, *TP53* mutation was associated with significantly worse LRFS (median 61 *vs* 104 months; *P* \< 0.001), DRFS (median 33 *vs* 46 months; *P* = 0.041), RFS (median 30 *vs* 46 months; *P* = 0.017) and OS (median 30 *vs* 55 months; *P* = 0.001) ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). Conversely, presence of *PIK3CA* or *AKT1* mutation did not significantly affect outcomes in HR-positive patients. Once again, when mutation in *PIK3CA* exon 9 was compared to mutation in *PIK3CA* exon 20, no significant difference was seen in RFS (41 *vs* 44 months; *P* = 0.449) or OS (55 *vs* 50 months; *P* = 0.953). In HER2-positive patients, presence of *TP53* mutation was associated with worse RFS (median 15 *vs* 31 months; *P* = 0.016) but not OS. No other significant differences were seen in the outcomes of HER2-positive or TNBC patients with the presence of mutation in *TP53, PIK3CA* or *AKT1*.

![*PIK3CA* Mutation is Associated with Better Outcomes\
Kaplan-Meier curves of LRFS, DRFS, RFS and OS in patients with and without *PIK3CA* mutations. *PIK3CA* mutation was associated with significantly better LRFS, RFS and OS and a trend towards better DRFS.](oncotarget-07-76362-g003){#F3}

In univariable analysis of RFS, age, clinical subtype, tumor grade, stage at diagnosis, administration of neoadjuvant or adjuvant chemotherapy and type of surgery were all significant or marginally significant predictors of outcome (Table [2](#T2){ref-type="table"}). After multivariable analysis with stratification of adjuvant chemotherapy, only tumor subtype, stage at diagnosis and *TP53* mutation remained significant predictors of RFS. In HR-positive patients, grade III disease, stage II disease at diagnosis, administration of neoadjuvant chemotherapy and *TP53* mutation were significant predictors of RFS after multivariable analysis. In both the entire cohort and HR-positive patients, *PIK3CA* and *AKT1* mutations were not significant predictors of RFS after multivariable analysis.

###### Univariable and Multivariable Analysis for RFS from Primary Cancer Diagnosis and OS from Diagnosis of Metastasis

  RFS FROM PRIMARY CANCER DIAGNOSIS                                                                                                             
  ------------------------------------- ------------------ -------------------------- ------------------ ------------------- ------------------ -------------
  **Age**                                                                                                                                       
   ≤ 50                                 0.059              1                                             0.231               1                  
   \> 50                                1.28(0.98-1.66)    0.066                      1.21 (0.90-1.65)   0.213                                  
  **Subtype**                                                                                                                                   
   HR-positive, HER2-negative                              1                                                                                    
   HER2-positive                        \<0.001            2.74 (1.59-4.72)           \<0.001                                                   
   TNBC                                                    1.58 (1.11-2.25)           0.011                                                     
  **Grade**                                                                                                                                     
   I-II                                 \<0.001            1                                             \<0.001             1                  
   III                                                     1.27 (0.97-1.65)           0.086                                  1.44 (1.07-1.94)   0.018
  **Stage at Diagnosis**                                                                                                                        
   0-I                                                     1                                                                 1                  
   II                                   \<0.001            1.58 (1.12-2.23)           0.009              \<0.001             1.73 (1.17-2.56)   0.006
   III                                                     1.99 (1.33-3.00)           0.001                                  1.47 (0.92-2.34)   0.110
  **Neoadjuvant Chemotherapy**                                                                                                                  
   No                                   \<0.001            1                                             \<0.001             1                  
   Yes                                  1.22 (0.93-1.60)   0.146                      1.66 (1.20-2.31)   0.003                                  
  **Surgery Type**                                                                                                                              
   Breast-Conserving                    0.005              1                                             0.030               1                  
   Mastectomy                           1.23 (0.91-1.66)   0.184                      1.35 (0.94-1.94)   0.101                                  
  **Mutation**                                                                                                                                  
   *AKT1*-mutated                                          0.89 (0.51-1.53)           0.663                                  0.92 (0.51-1.64)   0.770
   *PIK3CA*-mutated                                        0.85 (0.65-1.13)           0.266                                  0.83 (0.61-1.13)   0.241
   *TP53*-mutated                                          1.48 (1.10-1.98)           0.009                                  1.64 (1.15-2.33)   0.006
  **OS FROM DIAGNOSIS OF METASTASIS**                                                                                                           
                                        **All Patients**   **HR-Positive Patients**                                                             
  **Covariate**                         **Univariable**    **Multivariable**          **Univariable**    **Multivariable**                      
                                        **P Value**        **HR (95% CI)**            **P Value**        **P Value**         **HR(95%CI)**      **P Value**
  **Subtype**                                                                                                                                   
   HR-positive, HER2-negative           \<0.001            1                                                                                    
   HER2-positive                        0.28 (0.13-0.63)   0.002                                                                                
   TNBC                                 2.37 (1.57-3.58)   \<0.001                                                                              
  **Grade**                                                                                                                                     
   I-II                                 \<0.001            1                                             \< 0.001            1                  
   III                                  1.38 (0.97-1.96)   0.072                      1.50 (1.02-2.20)   0.037                                  
  **First Metastatic Site**                                                                                                                     
   Bone                                 0.058              1                                             0.168               1                  
   Visceral                             1.21 (0.85-1.73)   0.298                      1.57 (1.02-2.39)   0.038                                  
   Soft Tissue                          0.63 (0.37-1.08)   0.090                      0.52 (0.26-1.03)   0.064                                  
   Brain or Multiple                    1.44 (0.87-2.37)   0.154                      1.32 (0.69-2.53)   0.41                                   
  **Mutation**                                                                                                                                  
   *AKT1*-mutated                                          0.61 (0.24-1.52)           0.289                                  0.65 (0.26-1.65)   0.367
   *PIK3CA*-mutated                                        0.84 (0.58-1.22)           0.370                                  0.88 (0.59-1.32)   0.540
   *TP53*-mutated                                          1.44 (1.00-2.07)           0.048                                  2.20 (1.41-3.44)   0.001

In univariable analysis of OS, clinical subtype, tumor grade, stage at diagnosis and first site of distant metastatic disease were significant or marginally significant predictors of OS (Table 3). After multivariable analysis with stratification of stage, only tumor subtype and presence of *TP53* mutation remained significant predictors. In HR-positive patients, grade III disease, visceral metastatic disease and *TP53* mutation were significant predictors of OS after multivariable analysis. Again, in both the entire cohort and HR-positive patients, *PIK3CA* and *AKT1* mutations were not significant predictors of OS after multivariable analysis.

Analysis by therapy {#s2_4}
-------------------

TNBC patients had the worst overall TTP (median 6 months with first line therapy; median 3 months with second line therapy; and median 4 months with third line therapy), while HER2-positive patients had the best overall TTP (median 30 months with first line therapy; median 18 months with second line therapy; and median 11 months with third line therapy). In the overall patient population, targeted therapy was associated with better TTP with first (median 14) and second (median 14) line therapy. Conversely, patients treated with chemotherapy had the worst TTP with first (median 8 months) and second (median 6 months) line therapy.

*TP53* mutation was associated with significantly worse TTP with first (median 6 *vs* 13 months; *P* = 0.001) and second line therapy (median 4 *vs* 8 months; P = 0.018) ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). In patients treated with chemotherapy, *TP53* mutation was associated with significantly worse TTP with first (median 6 *vs* 8 months; *P* = 0.046) and second (3 *vs* 8 months; *P* = 0.003) line therapy. However, *PIK3CA* and *AKT1* mutations were not associated with changes in outcomes outcomes to TTP. Further, no association was found between *TP53, PIK3CA* and *AKT1* mutations and TTP in HR-positive patients treated with endocrine therapy.

Spectrum of *TP53* mutations {#s2_5}
----------------------------

The majority of *TP53* mutations were missense mutations (72%) ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). In patients with TNBC, the relative proportion of nonsense and frameshift mutations was increased compared to HR-positive and HER2-positive patients.

DISCUSSION {#s3}
==========

In this cohort of 500 MBC patients who underwent hotspot mutation testing, we describe the clinical characteristics and outcomes associated with the most frequently encountered mutations, *TP53, PIK3CA* and *AKT1*. Many large series report the incidence of these prevalent mutations in metastatic breast cancer patients, but few series correlate these mutations with clinical characteristics and outcomes in order to better understand their clinical impact. Patients in this cohort were evaluated for mutations in either the primary tumor, recurrent disease or both. As has been previously reported, when both primary and metastatic samples were analyzed, mutations between the two samples were generally concordant.\[[@R16]\]

Mutations in *TP53* and *PIK3CA* have previously been identified as of fundamental importance in cancer pathogenesis and resistance to therapy.\[[@R17]-[@R19]\]. The Cancer and Genome Atlas Project (TCGA) reported a high frequency of *TP53* (37%) and *PIK3CA* (36%) mutations in breast cancer patients.\[[@R11]\] *TP53* mutations were seen in the majority of basal-like cancers (80%), which is comprised mainly of TNBCs, and only in a minority of patients with Luminal A cancers (12%), which are strongly ER-positive tumors of low grade. Conversely, *PIK3CA* mutation was seen in 45% of Luminal A tumors, 39% of HER2-positive tumors and 9% of basal-like tumors. Similarly, sequencing of the METABRIC cohort revealed higher rates of *TP53* mutations in basal-like patients (65%) than Luminal A patients (9%).\[[@R20]\] We also found that that *TP53* mutation was more frequently encountered in TNBC patients, and *PIK3CA* mutation was more frequently encountered in HR-positive and HER2-positive patients. The incidence of *TP53* and *PIK3CA* mutation was comparatively lower in our cohort, and this is at least in part attributable to the platforms used in our study, as we assessed only hotspot mutations.

It is well established that the *TP53* tumor suppressor protein is frequently mutated in cancer.\[[@R21], [@R22]\] TP53 mutations have been found to confer a poor prognosis in several tumor types.\[[@R23]-[@R25]\] Most studies report that the *TP53* is mutated in about 30% of breast cancers. Despite this, the prognostic impact of *TP53* mutations across the different molecular subtypes of breast cancer is still poorly understood. This is at least in part due to the fact that *TP53* is a multi-functional protein, and mutations in different domains may impart different phenotypes that are biologically distinct.\[[@R12]\] While some studies have reported increased chemosensitivity in patients with *TP53* mutations,\[[@R26], [@R27]\] others have reported the opposite.\[[@R28]\] Interestingly, patients with *TP53* mutation had worse TTP in this cohort of patients, but it is unclear if this was due to the presence of *TP53* mutation or the prevalence of this mutation in TNBCs. Further, most studies of chemosensitivity have been done in the early disease setting, whereas patients in this study all had advanced disease. A recent study reported that *TP53* mutation was associated with worse outcomes overall and specifically in patients with HR-positive disease.\[[@R20]\] Similarly, in our cohort, *TP53* mutation remained a significant predictor of worse clinical outcomes after multivariable analysis in the overall cohort and HR-positive patients. Further, basal-like breast cancers have previously been associated with truncation mutations in *TP53*.\[[@R29]\] Similarly, there was a higher incidence of nonsense/frameshift *TP53* mutations in the TNBC subset compared to other subsets in this cohort. The predictive analysis of different TP53 mutations would be incomplete as we assessed only hotspot mutations and thus missed some of the *TP53* genomic alterations.

PI3K pathway aberrations, especially in the p110α catalytic domain of *PI3K* which is encoded by *PIK3CA*, are common in breast cancer.\[[@R30], [@R31]\] However, the impact of these aberrations on prognosis remains unclear. It has been demonstrated that PI3K pathway aberrations are inconsistently associated with activation of downstream signaling, indicating that different PI3K pathway aberrations are of variable significance.\[[@R32]\] Although most studies associate mutations in *PIK3CA* with improved outcomes in breast cancer, \[[@R13], [@R33]\] some studies associate them with worse outcomes.\[[@R15]\] This may be partly due to the significance of specific mutations; it has been suggested that mutations in exon 20 of *PIK3CA* (kinase domain) are associated with improved outcomes, while mutations in exon 9 (helical domain) are associated with worse outcomes.\[[@R34]\] Further, specific genome alterations of *PIK3CA* have been associated with worse outcomes.\[[@R35]\] Tumor evolution may also play a role as high levels of intra-tumor heterogeneity have been associated with worse outcomes.\[[@R35]\] Additionally, in patients with HR-positive and HER2-positive tumors, increased PI3K/AKT/mTOR signaling has been associated with resistance to endocrine and HER2-targeted therapies, respectively.\[[@R36]-[@R41]\] In this cohort of MBC patients, *PIK3CA* hotspot mutations were associated with better clinical outcomes. However, after multivariable analysis *PIK3CA* mutation did not remain a significant predictor of outcomes in the overall cohort or HR-positive patients. Thus, the association with outcomes may be due to the prevalence of *PIK3CA* mutations in HR-positive patients rather than an independent effect. Further, when mutations in exon 9 were compared to mutations in exon 20 in this cohort, no significant differences in outcomes were seen.

Although the number of matched primary and metastatic tumors were small, the data was notable for an overall concordance rate of 74%. There was discordance in potentially actionable genes such as *PIK3CA* with both gains and losses seen, with a slight trend towards enrichment for *TP53* mutations and mutations in the MAPK pathway in metastases/recurrences. The mutations detected only in metastatic pairs supports the clonal evolution pattern of development during tumor progression while the presence of mutations in the primary but not in the paired metastasis, suggests that metastatic tumor branched off from the primary before it acquired those mutations. This genomic evolution. suggests the role of biopsy of metastases for genomic testing. Further study is needed to evaluate impact of such genomic discordance on outcomes with genomically- targeted therapies, as well as circulating DNA mutation status in patients with mutation discordances between primary and metastases.

This study has several limitations. One of the greatest limitations of this study is that only hotspot mutations in specific genes of interest were evaluated. As a result, some of the aberrations present in the tumor samples remain unknown, and the impact of these aberrations on clinical outcomes is unclear. Further, hotspot testing limits association of specific aberrations with outcomes since the potential implications of other aberrations remain unknown. However, the increased cost of performing full sequencing prohibits such detailed evaluation of large cohorts of patients such as this one. Therefore, data presented here is hypothesis-generating, and conclusions need to be verified with more extensive sequencing data. Another limitation of this study is that samples were collected at various timepoints in treatment. Some tumor samples were collected prior to any treatment while others were collected after varying duration of treatment. It is well known that treatment can lead to selection of specific aberrations. Therefore, again, any data presented here would need to be further verified in a predictive, uniform patient analysis prior to clinical application. Finally, mutations predicted to be germline in this cohort were based on an informatics algorithm that assessed allelic frequency in tumor samples only. Therefore, mutations that were predicted to be germline but were actually somatic might have been excluded. Overall, the number of such mutations to be excluded should be small.

In summary, in this cohort of MBC patients, *TP53*, the most frequently encountered hotspot mutation, was associated with worse clinical outcomes, while *PIK3CA*, the second most frequently encountered hotspot mutation did not remain a significant predictor of outcomes after multivariable analysis. This study assesses the prognostic impact of common hotspot mutations in metastatic breast cancer patients. In order to incorporate these findings into clinical use, the predictive value of these findings needs to be established with more extensive sequencing analysis in a uniform clinical setting. Based on predictive models, biomarker-driven trials of genomically-informed therapy can be designed with novel targeted agents. Alternatively, these models could be used to predict sensitivity to currently used chemotherapeutic, hormonal or targeted agents to improve outcomes in breast cancer patients.

MATERIALS AND METHODS {#s4}
=====================

Patients with advanced disease who were felt to benefit from somatic genomic testing were enrolled on an Institutional Review Board-approved protocol at The University of Texas MD Anderson Cancer (NCT01772771). Tumor samples were obtained from 500 patients with metastatic breast cancer after informed consent. Clinical outcomes were collected by a retrospective review, supplementing a prospectively maintained database.

Tumor samples {#s4_1}
-------------

Testing was performed on archived tumor samples for most patients. Testing was requested on both the primary tumor and metastases if both samples were available. Specimens included formalin-fixed paraffin-embedded (FFPE) core needle biopsies and tumor resection specimens. Manual macrodissection of tumor-rich areas was performed, and only cases with \>20% tumor cellularity were included in this study.

Histologic grading was done using the Nottingham grading system combining nuclear grade, tubule formation and mitotic rate and assigning a combined score of 1 (low grade), 2 (intermediate grade), and 3 (high grade). Immunohistochemical (IHC) staining for estrogen receptor (antibody clone 6F11-Novacastra) and progesterone receptor (antibody clone PgR1294-DAKO) was scored as positive if ≥ 1% of tumor cell nuclei were immunoreactive.\[[@R42]\] IHC for HER2 was performed using antibody AB8 (NeoMarkers), and equivocal or indeterminate cases were evaluated by fluorescent in situ hybridization (FISH). HER2 status was scored according to current practice guidelines.\[[@R43]\] All histologic diagnoses, grading and IHC staining were evaluated by the breast pathology service at MD Anderson Cancer Center. Breast cancer subtypes were defined as: HR-positive (estrogen or progesterone receptor-positive and HER2-negative); HER2-positive (HER2-positive regardless of HR status) and TNBC (HR-negative and HER2-negative).

Genomic analysis {#s4_2}
----------------

DNA was extracted and amplified using standard methods.\[[@R44]\] Initially, the Sequenom multiplex assay was used to assess for single nucleotide variants and small insertions/deletions in hotspot regions in 11 genes: *AKT1, BRAF, GNAS, GNAQ, IDH1, IDH2, KRAS, MET, NRAS, PIK3CA* and *RET*. The Sequenom multiplex assay is based on distinguishing allele-specific primer extension products by mass spectrometry.\[[@R45]\] Later in the study, a 46 or 50 gene Ampliseq Ion Torrent Assay was used. This panel is a multiplex PCR-based library preparation method by which 190 regions (70-150 bp) that encompass 740 mutational hotspots in the coding sequence of 46 or 50 cancer-related genes are selectively amplified and subsequently analyzed for mutations using multiple markers of detection.\[[@R46]\] The following genes were included in the 46 gene panel: ABL1, *AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNAS, HNF1A, HRAS, IDH1, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NPM1, NOTCH1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53* and *VHL*.\[[@R47]\] The 50 gene panel also included *EZH2, GNA11, GNAQ* and *IDH2*.

Clinical outcomes {#s4_3}
-----------------

All patients were included in genomic analysis to assess frequencies of encountered mutations, but patients were excluded from outcomes analysis if they did not start systemic therapy at the time of diagnosis of metastatic disease or if they developed contralateral breast cancer prior to metastatic disease as it was unclear which cancer had metastasized. Treatment in the metastatic setting was conducted according to physician\'s choice. Some patients were enrolled in clinical trials based on encountered mutations. Relapse-free survival (RFS) was calculated from the date of initial breast cancer diagnosis to the date of first local or distant relapse, death or last follow-up. Distant relapse-free survival (DRFS) was calculated from the date of breast cancer diagnosis to the date of distant relapse, death, or last follow-up. Patients who had Stage IV disease at diagnosis, DRFS \< 3 months or did not have definitive surgery were excluded from RFS and DRFS analysis. Local-regional relapse-free survival (LRFS) was calculated from the date of definitive surgery to the date of first breast, chest wall, or ipsilateral nodal basin recurrence, death or last follow-up. Patients who developed distant recurrence prior to local recurrence were still included in LRFS analysis. However, only patients that underwent definitive surgery were included (*N* = 375). Overall survival (OS) was calculated from the date of diagnosis of distant disease to the date of death or last follow-up. Time to treatment failure due to progression (TTP) was calculated from the date of treatment start in the metastatic setting to date of treatment end due to progression. Patients that discontinued treatment due to completion of therapy, toxicity, loss to follow up or death were censored. For TTP analysis, patients were grouped by type of therapy (chemotherapy \[given alone or in combination with other agents\], hormonal therapy or targeted therapy \[including HER2-directed agents, mTOR inhibitors and agents on clinical trial, given alone or in combination with hormonal therapy but not in combination with chemotherapy\]) and line of therapy (first, second or third) in the metastatic setting.

Statistical analysis {#s4_4}
--------------------

Continuous variables were summarized using the median (range). Categorical variables were summarized by frequency and percent. Mutation rates were calculated based on the tested samples. The association between mutation status and categorical patient characteristics was assessed by Fisher\'s exact test. *P* values \< 0.05 were considered significant. The distribution of time to event endpoints were estimated by the method of Kaplan and Meier, and the comparison between groups was conducted by the log-rank test. Clinical variables which were significant or marginally significant (*P* \< 0.1) in univariable analysis were considered for inclusion in multivariable models. Cox proportional hazards model was used to evaluate the association between known prognostic and predictive clinical variables and patient outcomes in the multivariable analysis.
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